CD274 and non-small cell lung carcinoma: Unresectable stage III NSCLC accounts for 30% of NSCLC diagnoses, and its current standard treatment consists of concurrent chemo-radiotherapy followed by consolidation with Durvalumab in patients with PD-L1 ≥ 1%, with remarkable advantages in terms of progression-free survival (PFS) and overall survival (OS), as reported in the practice-changing PACIFIC trial and validated in several real-world experiences [47,48,49,50].